Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Nebenwirkungen · Yentreve
YENTREVE 20 mg hard gastro-resistant capsules YENTREVE 40 mg hard gastro-resistant capsules · Abschnitt 4.8 · PDF-Seite 8–9
HOS-112885 · Präparat HOS-093777
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
8
Very Common Uncommon Rare Very rare Not known
common
Infections and infestations
Laryngitis
Immune system disorders
Hyper- Anaphylactic
sensitivity reaction
disorder
Endocrine disorders
Hypo-
thyroidism
Metabolism and nutrition disorders
Appetite Dehydration Hyperglycaemi
decreased a (reported
especially in
diabetic
patients)
Hyponatraemia
SIADH6
Psychiatric disorders
Insomnia Bruxism Suicidal
Agitation Disorientation behaviour5,6
Libido Apathy Suicidal
decreased Orgasm ideation5,7
Anxiety abnormal Mania6
Sleep Abnormal Hallucinations
disorder dreams Aggression and
anger4,6
Nervous system disorders
Headache Nervousness Serotonin
Dizziness Disturbance syndrome6
Lethargy in attention Convulsions1,6
Somnolence Dysgeusia Myoclonus
Tremor Poor quality Akathisia6
Paraesthesia sleep Psychomotor
restlessness6
Extra-
pyramidal
symptoms6
Dyskinesia
Restless legs
syndrome
Eye disorders
Blurred Mydriasis Glaucoma
vision Visual
impairment
Dry eye
Ear and labyrinth disorders
Vertigo Tinnitus1
Ear pain
Cardiac disorders
Palpitations Supra- Stress
Tachycardia ventricular cardiomyopathy
arrhythmia, (Takotsubo
cardiomyopathy)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-09T15:33:00Z · SHA-256 d927c7a519b8bbcba3c7ad828fbbce3643ea8a3886fcc0403d91cbec6695f99d · Passage e80915802c36e64e454cc855fce9118ec220fea6710950a74a4033053b0c5e44 · Zeichen 1017–3986 im Abschnitt
Nebenwirkungen · Yentreve
YENTREVE 20 mg hard gastro-resistant capsules YENTREVE 40 mg hard gastro-resistant capsules · Abschnitt 4.8 · PDF-Seite 9–10
HOS-112886 · Präparat HOS-093777
9
Very Common Uncommon Rare Very rare Not known
common
mainly atrial
fibrillation6
Vascular disorders
Hypertensio Syncope2 Hypertensive
n3,7 Blood crisis3
Flushing pressure Orthostatic
increase3 hypotension2
Peripheral
coldness
Respiratory, thoracic and mediastinal disorders
Yawning Throat
tightness
Epistaxis
Interstitial lung
disease10
Eosinophilic
pneumonia6
Gastrointestinal disorders
Nausea Diarrhoea Gastrointestin Haematochezia
Dry mouth Abdominal al Microscopic
Constipation pain haemorrhage7 colitis9
Vomiting Gastroenteriti
Dyspepsia s
Stomatitis
Eructation
Gastritis
Dysphagia
Flatulence
Breath odour
Hepato-biliary disorders
Hepatitis3 Hepatic failure6
Elevated liver Jaundice6
enzymes
(ALT, AST,
alkaline
phosphatase)
Acute liver
injury
Skin and subcutaneous tissue disorders
Sweating Rash Stevens- Cutaneous
increased Night sweats Johnson vasculitis
Urticaria Syndrome6
Dermatitis Angio-neurotic
contact oedema6
Cold sweat Photo-
Increased sensitivity
tendency to reactions
bruise
Musculoskeletal and connective tissue disorders
Musculo- Muscle
skeletal pain twitching
Muscle
tightness
Muscle spasm
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-09T15:33:00Z · SHA-256 d927c7a519b8bbcba3c7ad828fbbce3643ea8a3886fcc0403d91cbec6695f99d · Passage 1ab612c65c5f66990617de1762d5251a9986ff663630175b0e10173b512dadf0 · Zeichen 4037–6842 im Abschnitt
Nebenwirkungen · Yentreve
YENTREVE 20 mg hard gastro-resistant capsules YENTREVE 40 mg hard gastro-resistant capsules · Abschnitt 4.8 · PDF-Seite 10–11
HOS-112887 · Präparat HOS-093777
10
Very Common Uncommon Rare Very rare Not known
common
Trismus
Renal and urinary disorders
Urinary Urinary
hesitation retention6
Dysuria Polyuria
Nocturia Urine flow
Pollakiuria decreased
Urine odour
abnormal
Reproductive system and breast disorders
Gynaecologic Menstrual
al disorder
haemorrhage Galactorrhoea
Menopausal Hyperprolactin
symptoms aemia
Postpartum
haemorrhage6
General disorders and administration site conditions
Fatigue Asthenia Chest pain7 Gait
Chills Falls 8
disturbance
Feeling
abnormal
Feeling cold
Thirst
Malaise
Feeling hot
Investigations
Weight Blood
decrease potassium
Weight increased
increase
Blood
cholesterol
increased
Blood
creatine
phosphokinas
e increased
1
Cases of convulsion and cases of tinnitus have also been reported after treatment discontinuation.
2
Cases of orthostatic hypotension and syncope have been reported especially at the initiation of
treatment.
3
See section 4.4.
4
Cases of aggression and anger have been reported particularly early in treatment or after treatment
discontinuation.
5
Cases of suicidal ideation and suicidal behaviours have been reported during duloxetine therapy or
early after treatment discontinuation (see section 4.4).
6
Estimated frequency of post-marketing surveillance reported adverse reactions; not observed in
placebo-controlled clinical trials.
7
Not statistically significantly different from placebo.
8
Falls were more common in the elderly (≥65 years old).
9
Estimated frequency based on all clinical trial data.
10
Estimated frequency based on placebo-controlled clinical trials.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-09T15:33:00Z · SHA-256 d927c7a519b8bbcba3c7ad828fbbce3643ea8a3886fcc0403d91cbec6695f99d · Passage a3a2f37bb4e6d8ef0ea32e6ef0373ea5aba3a3aeb5ba2d1339cd9b059c7462a9 · Zeichen 6893–9858 im Abschnitt
Nebenwirkungen · Yentreve
YENTREVE 20 mg hard gastro-resistant capsules YENTREVE 40 mg hard gastro-resistant capsules · Abschnitt 4.8 · PDF-Seite 11–12
HOS-112888 · Präparat HOS-093777
c. Description of selected adverse reactions
11
Discontinuation of duloxetine (particularly when abrupt) commonly leads to withdrawal symptoms.
Dizziness, sensory disturbances (including paraesthesia or electric shock-like sensations, particularly
in the head), sleep disturbances (including insomnia and intense dreams), fatigue, somnolence,
agitation or anxiety, nausea and/or vomiting, tremor, headache, myalgia, irritability, diarrhoea,
hyperhydrosis and vertigo are the most commonly reported reactions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-09T15:33:00Z · SHA-256 d927c7a519b8bbcba3c7ad828fbbce3643ea8a3886fcc0403d91cbec6695f99d · Passage 00f682f323b3611521bb18cf64e980c9464de96b438048f6e73008741f4f7809 · Zeichen 9860–10420 im Abschnitt
Nebenwirkungen · Yentreve
YENTREVE 20 mg hard gastro-resistant capsules YENTREVE 40 mg hard gastro-resistant capsules · Abschnitt 4.8 · PDF-Seite 12
HOS-112889 · Präparat HOS-093777
Generally, for SSRIs and SNRIs, these events are mild to moderate and self-limiting, however, in
some patients they may be severe and/or prolonged. It is therefore advised that when duloxetine
treatment is no longer required, gradual discontinuation by dose tapering should be carried out (see
sections 4.2 and 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-09T15:33:00Z · SHA-256 d927c7a519b8bbcba3c7ad828fbbce3643ea8a3886fcc0403d91cbec6695f99d · Passage 8f33c791de0609ba2fb9bca06e14a2139a6122ed47f16a1a38f069df62bd2e1c · Zeichen 10422–10738 im Abschnitt
Nebenwirkungen · Yentreve
YENTREVE 20 mg hard gastro-resistant capsules YENTREVE 40 mg hard gastro-resistant capsules · Abschnitt 4.8 · PDF-Seite 12
HOS-112890 · Präparat HOS-093777
The heart rate-corrected QT interval in duloxetine-treated patients did not differ from that seen in
placebo-treated patients. No clinically significant differences were observed for QT, PR, QRS, or
QTcB measurements between duloxetine-treated and placebo-treated patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-09T15:33:00Z · SHA-256 d927c7a519b8bbcba3c7ad828fbbce3643ea8a3886fcc0403d91cbec6695f99d · Passage 620df0f7b6e48f2196f2b4ac1c0664ec750f303a5074d810f37fe3952141e954 · Zeichen 10740–11013 im Abschnitt
Nebenwirkungen · Yentreve
YENTREVE 20 mg hard gastro-resistant capsules YENTREVE 40 mg hard gastro-resistant capsules · Abschnitt 4.8 · PDF-Seite 12
HOS-112891 · Präparat HOS-093777
In the 12 week acute phase of three clinical trials of duloxetine in patients with diabetic neuropathic
pain, small but statistically significant increases in fasting blood glucose were observed in duloxetine-
treated patients. HbA1c was stable in both duloxetine-treated and placebo-treated patients. In the
extension phase of these studies, which lasted up to 52 weeks, there was an increase in HbA1c in both
the duloxetine and routine care groups, but the mean increase was 0.3% greater in the duloxetine-
treated group. There was also a small increase in fasting blood glucose and in total cholesterol in
duloxetine-treated patients while those laboratory tests showed a slight decrease in the routine care
group.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-09T15:33:00Z · SHA-256 d927c7a519b8bbcba3c7ad828fbbce3643ea8a3886fcc0403d91cbec6695f99d · Passage b17ab7c9ab7dca68bc68adc24118c36fc4d76ed703cf80f8d7113f9c43b51a4c · Zeichen 11015–11732 im Abschnitt
Nebenwirkungen · Yentreve
YENTREVE 20 mg hard gastro-resistant capsules YENTREVE 40 mg hard gastro-resistant capsules · Abschnitt 4.8 · PDF-Seite 12
HOS-112892 · Präparat HOS-093777
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It
allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via the national reporting system
listed in Appendix V.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-09T15:33:00Z · SHA-256 d927c7a519b8bbcba3c7ad828fbbce3643ea8a3886fcc0403d91cbec6695f99d · Passage 42f7144177697b690f59b1bda795c3fd216297691cf296a2e1269a137feab3cd · Zeichen 11734–12089 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.